US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product

The prostate cancer nuclear medicine diagnostics market in the US was valued at US$ 194.47 million in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach US$ 431.76 million by 2027.

Driving factors of the prostate cancer nuclear medicine diagnostics market are rising prevalence of prostate cancer and the growth of innovative radiopharmaceuticals. However, factors such as strict guidelines for storage, production, and use of radiopharmaceuticals are likely to restrain the growth of the market during the forecast period.

Prostate cancer (PCa) is the fourth common cancer across the US in terms of occurrence. The rising prevalence of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. For instance, according to GLOBOCAN, in 2018, there were ~2,129,118 cases of cancer in the US. Among these cases, about 10% were prostate cancer, i.e., 212,783 incidences in 2018. Moreover, the country reported 28,705 deaths due to cancer. The organization has estimated the cases of prostate cancer to reach above 737,463 in the next 5 years. After skin cancer, prostate cancer is the most common cancer in the American male population. As per the data of the American Cancer Society, 2020, it was estimated that prostate cancer would be about 191,930 and can result in deaths of ~33,330 people from prostate cancer in the US in 2020. Prostate cancer is more likely to grow in older adults. Thus, the rising incidences of prostate cancer offer huge growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period.

The prostate cancer nuclear medicine diagnostics market in the US is segmented into type and PET product. Based on type, the market is further segmented into PET and SPECT. The PET segment secured the largest share of the market in 2019. The segment is also forecasted to record the highest growth rate in the market. Based on PET product, the market is further segmented into F-18, C-11, and Ga68-PSMA. The F-18 segment held the largest share of the market in 2019. However, Ga68-PSMA is estimated to register the highest CAGR in the market during the forecast period due to factors such as rising prevalence of prostate cancer, technological improvements in diagnosis systems, and its higher sensitivity and accuracy.

A few major primary and secondary references included in the report are Food and Drug Administration, World Health Organization (WHO), US Nuclear Regulatory Commission (NRC), American Cancer Society, and Centers for Medicare and Medicaid Services, Center for Drug Evaluation and Research (CDER).

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the prostate cancer nuclear medicine diagnostics market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the US prostate cancer nuclear medicine diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.